| 臺大學術典藏 |
2020-05-26T09:26:57Z |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|
CHIH-HSIN YANG; Sequist L.V; Geater S.L; Tsai C.-M; Mok T.S.K; Schuler M; Yamamoto N; Yu C.-J; Ou S.H.I; Zhou C; Massey D; Zazulina V; Wu Y.-L.; Wu Y.-L.;Zazulina V;Massey D;Zhou C;Ou S.H.I;Yu C.-J;Yamamoto N;Schuler M;Mok T.S.K;Tsai C.-M;Geater S.L;Sequist L.V;Chih-Hsin Yang |
| 臺大學術典藏 |
2020-05-26T09:26:49Z |
Alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer: A phase II global study
|
Spira A; Bordogna W; Balas B; Morcos P.N; Monnet A; Zeaiter A; Kim D.-W.; Kim D.-W.;Zeaiter A;Monnet A;Morcos P.N;Balas B;Bordogna W;Spira A;Mekhail T;Ramirez S.V;Bearz A;Moro-Sibilot D;Lena H;Hughes B;Chih-Hsin Yang;Govindan R;De Petris L;Ahn J.S;Ou S.-H.I; Ou S.-H.I; Ahn J.S; De Petris L; Govindan R; CHIH-HSIN YANG; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez S.V; Mekhail T |
| 臺大學術典藏 |
2020-05-26T09:26:43Z |
Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer
|
Ou S.-H.I.;Zeaiter A;Golding S;Bordogna W;Han J.-Y;Chih-Hsin Yang;Tessmer A;Dansin E;De Pas T;Crino L;Duruisseaux M;Moro-Sibilot D.L;Chiappori A;Kim D.-W;De Petris L;Camidge D.R;Socinski M.A;Gandhi L;Govindan R;Shaw A.T;Gadgeel S.M; Gadgeel S.M; Shaw A.T; Govindan R; Gandhi L; Socinski M.A; Camidge D.R; De Petris L; Kim D.-W; Chiappori A; Moro-Sibilot D.L; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; CHIH-HSIN YANG; Han J.-Y; Bordogna W; Golding S; Zeaiter A; Ou S.-H.I. |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry
|
Mok T.S.K; CHIH-HSIN YANG; Ou S.-H.I; Pall G; Froesch P; Zalcman G; Gandara D.R; Riess J.W; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild S.I; Shih J.-Y; Warth A; Muley T; Cabillic F; Mazières J; Drilon A.; Gautschi O;Milia J;Filleron T;Wolf J;Carbone D.P;Owen D;Camidge R;Narayanan V;Doebele R.C;Besse B;Remon-Masip J;Janne P.A;Awad M.M;Peled N;Byoung C.-C;Karp D.D;Van Den Heuvel M;Wakelee H.A;Neal J.W;Mok T.S.K;Chih-Hsin Yang;Ou S.-H.I;Pall G;Froesch P;Zalcman G;Gandara D.R;Riess J.W;Velcheti V;Zeidler K;Diebold J;Fr?h M;Michels S;Monnet I;Popat S;Rosell R;Karachaliou N;Rothschild S.I;Shih J.-Y;Warth A;Muley T;Cabillic F;Mazi?res J;Drilon A.; Gautschi O; Milia J; Filleron T; Wolf J; Carbone D.P; Owen D; Camidge R; Narayanan V; Doebele R.C; Besse B; Remon-Masip J; Janne P.A; Awad M.M; Peled N; Byoung C.-C; Karp D.D; Van Den Heuvel M; Wakelee H.A; Neal J.W |
| 臺大學術典藏 |
2020-05-26T09:26:36Z |
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
|
Shaw A.T.;Zeaiter A;Morcos P.N;Balas B;Bordogna W;Golding S;Dansin E;Ahn J.S;Popat S;Lena H;Crino L;Dingemans A.-M.C;Govindan R;Barlesi F;Kim D.-W;Gandhi L;Gadgeel S;De Petris L;Ou S.-H.I;Chih-Hsin Yang; CHIH-HSIN YANG; Ou S.-H.I; De Petris L; Gadgeel S; Gandhi L; Kim D.-W; Barlesi F; Govindan R; Dingemans A.-M.C; Crino L; Lena H; Popat S; Ahn J.S; Dansin E; Golding S; Bordogna W; Balas B; Morcos P.N; Zeaiter A; Shaw A.T. |
| 臺大學術典藏 |
2020-05-26T09:26:33Z |
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
|
Ou S.-H.I.;Kotb A;Gupta R;Liu S;Schulz M;De Marinis F;Kim D.-W;Dingemans A.-M.C;Chih-Hsin Yang;Crin? L;Barlesi F;Shaw A.T;Gadgeel S; Gadgeel S; Shaw A.T; Barlesi F; Crinò L; CHIH-HSIN YANG; Dingemans A.-M.C; Kim D.-W; De Marinis F; Schulz M; Liu S; Gupta R; Kotb A; Ou S.-H.I. |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving alectinib in the phase ii NP28673 and NP28761 studies
|
Gadgeel S;Shaw A.T;Barlesi F;Crino L;Chih-Hsin Yang;Dingemans A.-M;Kim D.-W;Marinis F;Schulz M;Liu S;Gupta R;Smoljanovic V;Ou S.-H.I.; Gadgeel S; Shaw A.T; Barlesi F; Crino L; CHIH-HSIN YANG; Dingemans A.-M; Kim D.-W; Marinis F; Schulz M; Liu S; Gupta R; Smoljanovic V; Ou S.-H.I. |
| 臺大學術典藏 |
2020-05-26T09:26:17Z |
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
|
Ou S.-H.I;Gadgeel S.M;Barlesi F;Chih-Hsin Yang;De Petris L;Kim D.-W;Govindan R;Dingemans A.-M;Crino L;L?na H;Popat S;Ahn J.S;Dansin E;Mitry E;M?ller B;Bordogna W;Balas B;Morcos P.N;Shaw A.T.; Ou S.-H.I; Gadgeel S.M; Barlesi F; CHIH-HSIN YANG; De Petris L; Kim D.-W; Govindan R; Dingemans A.-M; Crino L; Léna H; Popat S; Ahn J.S; Dansin E; Mitry E; Müller B; Bordogna W; Balas B; Morcos P.N; Shaw A.T. |
| 臺大學術典藏 |
2020-05-25T07:35:08Z |
Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations
|
Solomon B.J; Martini J.-F; Ou S.-H.I; Chiari R; Soo R.A; Bearz A; Li S; Thurm H; Chia-Chi Lin; Riely G.J; Bauer T.M; Shaw A.T. |
| 臺大學術典藏 |
2019 |
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1�V2 trial
|
Ou S.-H.I.;Li S;Abbattista A;Peltz G;Martini J.-F;Thurm H;Clancy J.S;Bauer T.M;Chia-Chi Lin;Kao S;Soo R.A;Besse B;Riely G.J;Chiari R;Solomon B.J;Shaw A.T; Shaw A.T; Solomon B.J; Chiari R; Riely G.J; Besse B; Soo R.A; Kao S; Chia-Chi Lin; Bauer T.M; Clancy J.S; Thurm H; Martini J.-F; Peltz G; Abbattista A; Li S; Ou S.-H.I. |
| 臺大學術典藏 |
2017 |
Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry
|
Gautschi O.;Milia J.;Filleron T.;Wolf J.;Carbone D.P.;Owen D.;Camidge R.;Narayanan V.;Doebele R.C.;Besse B.;Remon-Masip J.;Janne P.A.;Awad M.M.;Peled N.;Byoung C.-C.;Karp D.D.;Van Den Heuvel M.;Wakelee H.A.;Neal J.W.;Mok T.S.K.;Yang J.C.H.;Ou S.-H.I.;Pall G.;Froesch P.;Zalcman G.;Gandara D.R.;Riess J.W.;Velcheti V.;Zeidler K.;Diebold J.;Fr?H M.;Michels S.;Monnet I.;Popat S.;Rosell R.;Karachaliou N.;Rothschild S.I.;Jin-Yuan Shih;Warth A.;Muley T.;Cabillic F.;Mazi?Res J.;Drilon A.; Michels S.; Monnet I.; Popat S.; Rosell R.; Karachaliou N.; Rothschild S.I.; JIN-YUAN SHIH; Warth A.; Muley T.; Cabillic F.; Mazi?res J.; Drilon A.; Gautschi O.; Milia J.; Filleron T.; Wolf J.; Carbone D.P.; Owen D.; Camidge R.; Narayanan V.; Doebele R.C.; Besse B.; Remon-Masip J.; Janne P.A.; Awad M.M.; Peled N.; Byoung C.-C.; Karp D.D.; Van Den Heuvel M.; Wakelee H.A.; Neal J.W.; Mok T.S.K.; Yang J.C.H.; Ou S.-H.I.; Pall G.; Froesch P.; Zalcman G.; Gandara D.R.; Riess J.W.; Velcheti V.; Zeidler K.; Diebold J.; Fr?h M. |
| 國立臺灣大學 |
2016 |
Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
|
Gandhi, L.; Gadgeel, S.; Shaw, A.; Barlesi, F.; Crino, L.; Yang, J. C-H.; Dingemans, A-M. C.; Kim, D-W.; de Marinis, F.; Schulz, M.; Liu, S.; Fish, S.; Kotb, A.; Ou, S-H. I.; 楊志新 |
